BioNTech Signs a Purchase Agreement to Acquire Kite's Cell Therapy- R&D Platform and Manufacturing Facility in Gaithersburg- MD
Shots:
- Kite will receive a one-time upfront to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform- R&D & clinical manufacturing facility in Gaithersburg. The Transaction is expected to be close at the end of Jul’21
- BioNTech will use the Kite’s facility to support clinical trials in the US & will add its cell therapy manufacturing facility in Idar-Oberstein- Germany
- The agreement will strengthen BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adds the manufacturing footprint in North America
Ref: Globenewswire | Image: Money Control
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com